Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
|Poll|January 6, 2015
Mini-quiz: Depression and Early Life Trauma
Author(s)Psychiatric Times Editors
Do persons with depression and a history of early life trauma benefit more from psychotherapy or pharmacotherapy? Take the quiz and learn more.
Advertisement
Advertisement
Related to this article
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Real-World Burden of Adult ADHD
2
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
3
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
4
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
5